SCHEMBL30912174

CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.64

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	10/20	0.64

▸	CCKBR	P32239	9/20	0.60

▸	ECE1	P42892	1/20	0.60

▸	MUS81	Q96NY9	1/20	0.60

▸	CCKAR	P32238	1/20	0.58

▸	OPRD1	P41143	1/20	0.58

▸	IL23R	Q5VWK5	1/20	0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30912173	0.91	GLP1R (0.52)	GLP1RECE1MUS81OPRD1
SCHEMBL30257955	0.89	GLP1R (0.70)	GLP1RCCKBRECE1MUS81IL23R
SCHEMBL30906488	0.87	GLP1R (0.66)	GLP1RCCKBRECE1MUS81CCKAR
SCHEMBL30906555	0.86	GLP1R (0.68)	GLP1RCCKBRECE1MUS81IL23R
SCHEMBL30906506	0.86	GLP1R (0.68)	GLP1RCCKBRECE1MUS81IL23R
SCHEMBL29943233	0.86	GLP1R (0.79)	GLP1RCCKBRECE1MUS81
SCHEMBL30906510	0.86	GLP1R (0.67)	GLP1RCCKBRECE1MUS81IL23R
SCHEMBL3356603	0.86	GLP1R (0.67)	GLP1RCCKBRECE1MUS81
SCHEMBL31371486	0.85	MAGI3 (0.60)	GLP1RCCKBRECE1MUS81CCKAR
SCHEMBL29597475	0.85	IL23R (0.61)	CCKBRCCKAROPRD1IL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-112969711-B	Desensitization and improvement of kidney transplantation in HLA sensitized patients using cladagumab	西达赛奈医疗中心	2024-12-17	—	—	CN	disclosed
CN-113194996-B	Clazazumab for the treatment of chronic antibody-mediated organ transplant rejection	西达赛奈医疗中心	2024-06-28	—	—	CN	disclosed